Year: 2023

Clariti to be PharmAla’s exclusive Long-Term Strategic Advisory and Investment Banking Partner VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has signed an exclusive long-term agreement (the “Partnership Agreement”) with Clariti Strategic Advisors Inc. (“Clariti”) of Toronto, pursuant to which Clariti will provide strategic advisory and investment banking services to the Company. Clariti will provide advice to help PharmAla ensure that its long-term value to its stakeholders is at all times being considered and optimized. Clariti, its subsidiaries and sub-agents will also advise...

CARSON CITY, NV, Nov. 08, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – LeapCharger Corporation (OTC: LCCN) (“LeapCharger” or the “Company”), an electric vehicle (EV) charging company with disruptive and innovative technology providing eco-friendly and sustainable solutions, today announced that its Chairperson and Chief Executive Officer, Praveenkumar Vijayakumar, will be participating in a live interview in the coming days to be hosted by The Tomorrow Investor on www.tomorrowinvestor.com, an entity affiliated with Think Ink Marketing Data & Email Services, Inc. The event will be broadcast live and a link for the streaming interview will be announced shortly via press release and on our social media pages. An archived recording of the presentation will also be available following its conclusion on www.tomorrowinvestor.com. Praveenkumar...

POMPANO BEACH, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279 for VENDAJE AC® pursuant to its application for Healthcare Common Procedure Coding System (HCPCS) “Q” codes. The HCPCS code assigned for VENDAJE AC® will be effective January 1st, 2024. VENDAJE AC is a human connective tissue matrix comprised of dehydrated amniotic/chorionic tissue processed using BioStem’s proprietary BioREtain® process. It is an easy to handle, thicker structural tissue allograft, intended for use as a protective covering for soft tissue wounds. Q codes are...

Management Presentation to be Webcast Live at 10:45 AM ET on November 16, 2023 PRINCETON JUNCTION, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE) – a leading “one source” multinational provider of technology-enabled asset protection solutions used to maximize the uptime and safety of critical energy, industrial, and public infrastructure – announced today that Edward Prajzner, Senior Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti Micro Cap Virtual Conference, being held from November 15-16, 2023. The presentation will begin at 10:45 AM ET on November 16. To register to attend and access the presentation, please visit https://sidoti.zoom.us/webinar/register/WN_8wiOxOLcT4KjNB4GUebqaw#/registration. Management will also be available for one-on-one meetings throughout the...

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have demonstrated proof of technology with our third clinical program, as well as our first proof of mechanism in our UB-312 program for Parkinson’s. We have observed clear target engagement with aggregated alpha-synuclein in patient CSF, indicating that UB-312-induced antibodies cross the blood-brain barrier and engage the toxic pathology of...

Aspo PlcInside informationNovember 8, 2023 at 3:30 p.m. Inside information: Aspo announces partnership with OP Finland Infrastructure LP to accelerate the green transition of Aspo’s subsidiary ESL Shipping In April this year Aspo announced that it has initiated a program to accelerate ESL Shipping’s green transition through a program assessing three alternative measures, including a launch of a new investment pool of fossil-free vessels, a possible equity injection in ESL Shipping by a minority shareholder, and the sales of the shipping company’s two Supramax vessels. As the first result of this assessment, Aspo has today signed an agreement with OP Finland Infrastructure LP regarding an investment of EUR 30 million into Aspo’s subsidiary ESL Shipping. The investment will be made against issuance of new shares in ESL Shipping with an agreed...